Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: methodology of clinical trials and clinical benefit

• Published in: Cancer treatment reviews Vol. 53; pp. 53 - 60
• Main Authors: Dos Santos, M, Brachet, P.E, Chevreau, C, Joly, F
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.02.2017
• Subjects: Antineoplastic Agents - therapeutic use; Bevacizumab - therapeutic use; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - mortality; Carcinoma, Renal Cell - pathology; Clinical benefit; Hematology, Oncology and Palliative Medicine; Humans; Kidney Neoplasms - drug therapy; Kidney Neoplasms - mortality; Kidney Neoplasms - pathology; Metastatic renal cell carcinoma; Molecular Targeted Therapy - methods; Niacinamide - analogs & derivatives; Niacinamide - therapeutic use; Patient-reported outcomes; Phenylurea Compounds - therapeutic use; Quality of Life; Randomized clinical trials; Randomized Controlled Trials as Topic; Sirolimus - analogs & derivatives; Sirolimus - therapeutic use; Target therapy; Treatment Outcome; Metastatic renal cell carcinoma; Clinical benefit; Patient-reported outcomes; Randomized clinical trials; Target therapy; Quality of life
• ISSN: 0305-7372; 1532-1967
• DOI: 10.1016/j.ctrv.2016.12.003

Highlights • Metastatic renal cell carcinoma is an incurable cancer. • Gain in progression-free survival with new drugs is around 3 months. • Patient-reported outcomes are an essential endpoint with strong impact on clinical benefit. • The quality of the methodology and the data analysis of patient-reported outcomes are not yet optimal. • New-generation therapies should demonstrate not only a gain in survival but also in quality of life.